#1699 On the Pen with David Knapp
You can always listen to the Juicebox Podcast here but the cool kids use: Apple Podcasts/iOS - Spotify - Amazon Music - Google Play/Android - iHeart Radio - Radio Public, Amazon Alexa or wherever they get audio.
Scott and Dave Knapp break down GLP-1 medications, weight loss, metabolic health, inflammation, type 1 impacts, myths, microdosing, and why these drugs may reshape diabetes care.
+ Click for EPISODE TRANSCRIPT
DISCLAIMER: This text is the output of AI based transcribing from an audio recording. Although the transcription is largely accurate, in some cases it is incomplete or inaccurate due to inaudible passages or transcription errors and should not be treated as an authoritative record. Nothing that you read here constitutes advice medical or otherwise. Always consult with a healthcare professional before making changes to a healthcare plan.
Scott Benner (0:00) Friends, we're all back together for the next episode of the Juice Box podcast. (0:04) Welcome.
David Knapp (0:14) I'm Dave Knapp. (0:15) I'm the founder of the On the Pen Podcast. (0:18) It is a weekly podcast all about the news around these new medications that I'm sure that you've heard about, the Ozempic's of the world, the Majoros of the world. (0:27) Maybe you've heard it as the fat shot too from the Oval Office. (0:31) But however you've heard of it, you've heard of it by now.
David Knapp (0:33) These medications are taking the world by storm. (0:36) And I, as a type two diabetic diagnosed in the 2021, ended up on these medications after trying everything in my own power and my own might and even looking down the barrel of a metabolic surgery that would have rearranged my anatomy. (0:51) And my doctor introduced me to these medications, and I thought, you know what? (0:54) There's no one that is giving this information from the patient perspective. (0:58) Everything that's out there is for a doctor.
David Knapp (1:01) It's for an investor, but nothing exists for the patients. (1:05) And that's where On the Pen came in. (1:06) So, Scott, I'm super excited to be sharing with you a little bit today about what we talk about over at On the Pen, my favorite subject, GLP one medications.
Scott Benner (1:16) Nothing you hear on the juice box podcast should be considered advice, medical or otherwise. (1:21) Always consult a physician before making any changes to your health care plan. (1:30) Just in time for the holidays, Cozy Earth is back with a great offer for Juice Box podcast listeners. (1:36) That's right. (1:36) Black Friday has come early at cozyearth.com.
Scott Benner (1:40) And right now, you can stack my code juice box on top of their site wide sale, giving you up to 40 off in savings. (1:48) These deals will not last, so start your holiday shopping today by going to cozyearth.com and using the offer code juice box at checkout. (1:56) The podcast is also sponsored today by Omnipod five. (2:00) Omnipod five is a tube free automated insulin delivery system that's been shown to significantly improve a one c and time and range for people with type one diabetes when they've switched from daily injections. (2:11) Learn more and get started today at omnipod.com/juicebox.
Scott Benner (2:16) At my link, you can get a free starter kit right now. (2:18) Terms and conditions apply. (2:19) Eligibility may vary. (2:21) Full terms and conditions can be found at omnipod.com/juicebox. (2:26) Today's episode is also sponsored by US Med.
Scott Benner (2:30) Usmed.com/juicebox or call (888) 721-1514. (2:36) Get your supplies the same way we do from USMed.
David Knapp (2:40) I'm Dave Knapp. (2:41) I'm the founder of the On the Pen Podcast. (2:44) It is a weekly podcast all about the news around these new medications that I'm sure that you've heard about, the Ozempic's of the world, the Majoros of the world. (2:53) Maybe you've heard it as the fat shot too from the Oval Office. (2:56) But however you've heard of it, you've heard of it by now.
David Knapp (2:59) These medications are taking the world by storm, and I, as a type two diabetic diagnosed in the 2021, ended up on these medications after trying everything in my own power and my own might and even looking down the barrel of a metabolic surgery that would have rearranged my anatomy. (3:17) And my doctor introduced me to these medications, and I thought, you know what? (3:20) There's no one that is giving this information from the patient perspective. (3:24) Everything that's out there is for a doctor. (3:26) It's for an investor, but nothing exists for the patients.
David Knapp (3:30) And that's where On the Pen came in. (3:32) So, Scott, I'm super excited to be sharing with you a little bit today about what we talk about over at On the Pen, my favorite subject, GLP one medications.
Scott Benner (3:40) Dave, I can't thank you enough for doing this. (3:42) Also, I'm I'm super amused not amused, but, like, kinda delighted watching you because you're accustomed to being on video, and I'm not. (3:48) I'm watching you be effusive and move around and smile and everything.
David Knapp (3:51) Like a maniac.
Scott Benner (3:52) Yeah. (3:53) And I realized that normally what would happen here is you and I wouldn't be looking at each other. (3:57) I would spin a 180 degrees, put my feet up over here and bring this microphone over and I and I would chat like that. (4:02) Yeah. (4:02) Yeah.
Scott Benner (4:02) So it's it's really awesome. (4:04) Well, listen, man. (4:05) I I appreciate you doing this. (4:07) I wanted to do it for a couple of reasons. (4:08) But mainly, I'm most interested maybe in a guy like you who's not a doctor, right, who does not have a medical background, who just found himself flung into this, who started making content and then realized that it was a business.
Scott Benner (4:22) Because of that, I think that you're steeped in it in a different way. (4:26) You don't get an opportunity often to talk to people who are paying a crazy amount of attention to one focused idea. (4:33) And when I realized that you're out there making, like, you know, news clips about, like, hey, there's a pill coming. (4:39) There's this. (4:39) Like, it's stuff we talk about here.
Scott Benner (4:41) Like, oh, I heard there's a pill coming. (4:43) I heard it's going to be as effective as the injectable maybe. (4:47) But I heard that from a doctor I had on, like, six months ago, you know Yeah. (4:50) Who just said to me, like, it's coming in oral form. (4:53) And, like and it's kinda how he put it.
Scott Benner (4:55) And I was like, what do mean? (4:56) He goes, oh, it's coming fast. (4:57) I wanna know what that means, but I don't have the time to dig through it. (5:00) Mhmm. (5:00) I'm digging through type one diabetes and and this podcast.
Scott Benner (5:04) So I'm I'm here to pick your brain and and everything, but I do wanna get a little background first. (5:08) So you said you're you have type two?
David Knapp (5:10) Yeah. (5:10) So I was diagnosed with type two diabetes back in the 2021. (5:15) This was after a year of experiencing what I called, like, level sleepiness. (5:21) I just knew something was wrong. (5:22) I thought maybe it was long COVID.
David Knapp (5:24) And I went into my doctor's office, and I said I knew that something's wrong. (5:28) What's going on? (5:28) And I was having kidney stones and just kind of a host of, I don't know, ailments that I just knew something was wrong. (5:33) I said to my wife, I said, either I have cancer, I'm dying, or I I have some sort of chronic disease. (5:38) The way I'm feeling is not normal.
David Knapp (5:40) Right. (5:40) And I went in, and the doctor checked my blood sugar. (5:43) He goes, the way that you're feeling is because you're type two diabetic. (5:46) And I said, what? (5:47) Like, record scratch.
David Knapp (5:48) Like, hey. (5:49) I didn't have the typical, like, to type two diabetes that you hear about where, hey. (5:54) Your a one c is creeping up, man. (5:56) Stay off the Twizzlers, whatever. (5:58) You know?
Scott Benner (5:58) Yeah.
David Knapp (5:59) I went from zero to a 100. (6:01) It had never sort of crept up on me. (6:03) Never had any warning other than the fact that I have been overweight my entire adult life, and we have this thing, this type two diabetes in my family. (6:11) I'm sort of skeptical that the coronavirus maybe kicked some people who were metabolically predisposed based upon the virus going through your body, that it had a metabolic effect on some people. (6:23) But that's definitely a conversation for a different day.
David Knapp (6:26) But, yeah, I was diagnosed with type two back in the 2021, and it was definitely a journey of I wanna try everything in my own within my own willpower Yeah. (6:36) To sort of will this disease away.
Scott Benner (6:38) How would you describe like, you know, I'm I'm sure you've probably shared this a million times. (6:42) I always end up apologizing to people first. (6:44) But, like, what was your height and weight at your diagnosis, and how would you describe your heat your eating habits at that time?
David Knapp (6:50) Yeah. (6:51) So my my height, is five ten, and my weight at that time was three hundred and nineteen pounds. (6:58) So we're talking a bit about a BMI in the upper forties, which is very, very high, morbidly obese. (7:03) What I was eating it's kind of hard to explain for somebody who's never lived with the disease of obesity. (7:08) Right?
David Knapp (7:08) Because obesity is a disease. (7:10) It's has profound metabolic effect that make it very difficult to to get your weight down. (7:15) But when we talk about what I was eating, well, I had actually yo yoed on the ketogenic diet from the time I was about 18, which is when I started really putting on noticeable weight. (7:26) Like, I even from a an adolescent, I could tell I was a little chubby, you know, to carry a little bit around my midsection that friends or family members didn't. (7:34) But then it wasn't until high school that I really started to see that there was kind of a separation in the way that my body was handling the foods I ate, etcetera.
David Knapp (7:42) I discovered this diet that everybody was kinda doing back then. (7:46) It's kinda like the GLP one of today. (7:47) It was the Atkins diet. (7:48) It was the low carb diet. (7:50) And so I started this journey where I I would get on the low carb diet, and it would work really, really well for me for about six months.
David Knapp (7:58) Like, I think the first time I went on it, I was I had got up to two hundred and twenty pounds. (8:03) And the first time I went on it within about six months, I think I was down to one seventy. (8:08) But, you know, the metabolism of an 18, 19 year old kid, not a 40 year old man. (8:14) Mhmm. (8:14) But I I sort of chased that because I could maintain it for about six months out of the year, and then for the other six months, I'd fall off the wagon hard.
David Knapp (8:22) So the way I kinda describe it when I tell this story, Scott, is I'd be up or I would be down 40 pounds, and then I'd be up 50 pounds. (8:32) And I'd be down 40 pounds and up 50 pounds, and there were different variations of that yo yo. (8:37) Yeah. (8:37) But every time on the upswing, it was up. (8:39) And so first of all, just imagine what that does to your body metabolically, like that swing back and forth and back and forth and back and forth for essentially, like, seventeen, eighteen years.
David Knapp (8:49) Wow. (8:49) And so, like, that year when I was diagnosed with diabetes, it wasn't really that much different than any other year. (8:54) I had just come off of six months of being very strict with my ketogenic diet, which is actually why I thought that I was experiencing kidney stones because I had had that happen before. (9:04) But, you know, I was minding my p's and q's. (9:07) I've never been a real sugar consumer like you may think of somebody who becomes diabetic at that age.
David Knapp (9:14) I wasn't a candy eater, still not a candy eater, wasn't a sugary soda drinker, although I've always been a diet soda drinker. (9:22) You know? (9:23) So I wasn't kinda like, in my mind, even though I was overweight, I didn't really fit the bill for somebody who was gonna go in at 36 and get a type two diabetes diagnosis. (9:31) I mean, you might the average person might go, well, you're a BMI of forty five. (9:35) What do you expect?
David Knapp (9:36) Well, I've been doing this podcast now for three years. (9:39) I've met people who are six or seven hundred pounds that aren't type two diabetic. (9:43) Mhmm. (9:44) You know, it was just it it was weird for me. (9:46) It was it was definitely a scary thing to get that diagnosis young because you know the implications in terms of what that does to somebody's expected lifespan.
David Knapp (9:55) And so the only thing I could think about, Scott, was my kids. (9:57) Like, what am I gonna do? (9:59) Like, how how am I gonna whip this thing into shape so that I can be around, with for my kids? (10:03) Because my dad own dad died of a massive heart attack at 54.
Scott Benner (10:06) Did he?
David Knapp (10:07) Yeah. (10:08) So No kidding.
Scott Benner (10:08) My story is not much different than yours, to be perfectly honest. (10:11) I never thought of myself as an incredibly poor eater. (10:14) I do look back now in hindsight and realize I grew up pretty broke, we ate some trashy food that I I wouldn't eat now. (10:20) But at the same time, it wasn't a massive amount. (10:23) It wasn't, like, constantly sugar or constantly this.
Scott Benner (10:26) And as an adult, a young adult, my wife and I did the same thing. (10:29) We were like, oh, we'll try the Atkins diet. (10:31) Mhmm. (10:31) And it did work. (10:32) Like, I was like, I I lost, like, 40 pounds.
Scott Benner (10:34) I was like, oh, magic. (10:35) Until one day, you just wake up and you're like, I can't eat another chicken wing. (10:39) I I've run out of things to to eat. (10:41) You know?
David Knapp (10:41) I've eaten enough stacks of hamburgers. (10:43) It's just just give me a bun.
Scott Benner (10:45) I think when you realize you're in trouble is when you're, like, you're out for the day driving around and you're hungry and you end up in, a drive through at a fast food restaurant, like, pulling the patties off and you're realizing, don't even think this is meat. (10:58) And you're you're like, well, at least there's no carbs in
David Knapp (11:01) it. (11:01) Right.
Scott Benner (11:02) And yeah. (11:03) So it just didn't work for me. (11:04) Then I slowly began I never had a type two diagnosis, and I don't think I was ever actually near one, luckily, though. (11:10) Like, I just think it's random because I was I'm five nine, and I was two hundred and thirty six pounds when I started using GLP. (11:18) You know, I know my body at that point.
Scott Benner (11:20) Like, I can't imagine what you were dealing with over three hundred pounds at that height. (11:24) Like, it must have been it really just difficult on you and your body and even psychologically, I I imagine it was not pleasant.
David Knapp (11:30) Yeah. (11:31) The the definitely the the upswing and the downswing. (11:34) And then you get used to this, kind of cycle of positive reinforcement from the people around you because when you're on the downswing, people are like, you look great. (11:41) And then you're kinda like, oh, you know, what are these people thinking of me when I'm on the upswing? (11:46) And then you you start to worry about all the people you're letting down and yeah.
Scott Benner (11:50) Oh, man. (11:50) When the first time I went into where did it happen to me first, maybe? (11:54) It was a friend I bumped into, then it was a post office that I only go to yearly. (11:58) Like, there's this one post office I used to mail my taxes. (12:01) And, like, so I don't see this lady very often, but it's a small post office.
Scott Benner (12:04) And I walked in and she made eye contact. (12:06) She recognized it was me, then she looked horrified, then she got quiet, and then she didn't know what to say. (12:13) And I realized, because I had been through it now twice before, I put my hand out. (12:16) I went, I don't have cancer. (12:18) She goes, oh, thank God.
Scott Benner (12:20) She's like, you lost so much weight. (12:22) I I just thought maybe you had cancer. (12:23) And I was like, I know. (12:24) And I said, I'm it's okay that you feel that way. (12:27) You're, like, maybe the fourth person that this has happened to me with.
Scott Benner (12:30) Yeah. (12:30) And that to your point, what in the hell did I look like before? (12:34) It's like right? (12:37) That, standing in front of her at a reasonable weight, she was like, uh-oh. (12:40) This one's on its So, way anyway, it it is it's been very transformational for me.
Scott Benner (12:46) But I kinda wanna, like, jump ahead a little bit. (12:49) Yeah. (12:49) Because you start making your thing you started on YouTube, I guess. (12:53) Right?
David Knapp (12:53) Yeah.
Scott Benner (12:54) Yeah. (12:54) Yep. (12:55) And tell me what got you doing that, why you why you did that. (13:00) Today's episode is brought to you by Omnipod. (13:02) We talk a lot about ways to lower your a one c on this podcast.
Scott Benner (13:07) Did you know that the Omnipod five was shown to lower a one c? (13:10) That's right. (13:11) Omnipod five is a tube free automated insulin delivery system, and it was shown to significantly improve a one c and time and range for people with type one diabetes when they switched from daily injections. (13:23) My daughter is about to turn 21 years old, and she has been wearing an Omnipod every day since she was four. (13:30) It has been a friend to our family, and I think it could be a friend to yours.
Scott Benner (13:33) If you're ready to try Omnipod five for yourself or your family, use my link now to get started. (13:40) Omnipod.com/juicebox. (13:43) Get that free Omnipod five starter kit today. (13:46) Terms and conditions apply. (13:47) Eligibility may vary.
Scott Benner (13:48) Full terms and conditions can be found at omnipod.com/juicebox. (13:54) Perhaps the best gift that you can give to yourself or to a loved one is that of comfort. (13:59) And this holiday season, if you use the offer code juice box at checkout at cozyearth.com, you won't just be getting something that's comfortable, you'll also be doing it at quite a discount. (14:10) We can talk about that in just a moment. (14:12) Right now, I wanna tell you that I use Cozy Earth towels every day when I get out of the shower.
Scott Benner (14:17) I sleep on Cozy Earth sheets every night when I get into bed. (14:21) I'm recording right now in a pair of Cozy Earth sweatpants. (14:25) I love their joggers, their hoodies, their shirts. (14:28) My wife has their pajamas. (14:30) And I know you're thinking, oh, yeah, Scott.
Scott Benner (14:31) Well, because they sent you a bunch of it for free. (14:33) They did send me some for free, but I've also bought a lot on my own. (14:37) So like I said earlier, Black Friday has come early at Cozy Earth. (14:41) And right now, you can stack my code JuiceBox on top of their site wide sale, giving you up to 40% off in savings. (14:49) These deals are definitely not gonna last.
Scott Benner (14:51) Get your shopping done now or get yourself something terrific at cozyearth.com. (14:56) Do not forget to use that offer code, Juice Box, at checkout. (14:59) You will not be sorry.
David Knapp (15:01) Yeah. (15:01) I mean, I was really, really wanting to learn more about these medications and how they worked and what they did in your body. (15:10) And I just I wasn't eager to take a drug, to be honest with you, which I think has really set me up great to lead this community because I think there's a lot of people who are reticent to take a drug, especially for obesity. (15:21) But I wanted to learn everything there was to learn about these medications. (15:25) And so when I went to YouTube or, you know, like any good millennial, that's that's where we learn things.
David Knapp (15:31) Right? (15:31) Mhmm. (15:31) So when I went there, there was a lot of really amazing stories about, hey. (15:34) I lost a 100 pounds with Ozempic. (15:36) There was nobody saying, this is how it worked, and these were the side effects that I had, and this is how they discovered these medications.
David Knapp (15:43) Like, all the things that I would want to know about these medications didn't exist there. (15:48) And so while it started as like a, hey. (15:50) This is me taking my first shot. (15:52) Look at me go. (15:52) Woo.
David Knapp (15:53) It very quickly developed into as I was reading clinical trial data, as I and I started following the Eli Lilly earnings calls almost immediately too, and then I started sharing because I was like, well, you know, you talked earlier about the pills. (16:08) Right? (16:08) Yeah. (16:08) I've actually been talking about these pills now for two and a half years because they were being talked about on these earnings calls where they were saying, you know, hey. (16:18) We're we're in, you know, phase one development for like, Eli Lilly has this one called orforglipron, which is coming out in a couple of months here.
David Knapp (16:27) You know? (16:27) And so we were talking about orforglipron two years ago because I started to see not only are these medications that appear to be changing so many people's lives, the ones that are here, there's medicines down the pike that are really gonna help people who have advanced metabolic disease. (16:42) And I've been somebody who's kinda struggled to lose a ton of weight on these, although I'm right where you would expect a diabetic to be based upon the diabetic clinical trials for weight loss. (16:51) You know, there's hope down the pike too for people who are more seriously sick. (16:55) And so really just wanted to start sharing that side of it, which is really sort of what exploded the work that I'm doing.
David Knapp (17:02) And then one of the crazy things, and we we may see some more of this in the coming months with the expansion of these drugs to Medicare, but when I first started these medications and people were learning about them, it was the heyday of GLP one because you could get Mounjaro without a type two diagnosis for $25 a month. (17:20) In those early days, they had a coupon.
Scott Benner (17:22) Really? (17:22) How long ago was that?
David Knapp (17:23) This was 2022. (17:25) At the 2022, around the time I first started, you could literally download a coupon, and it didn't matter if it you had it covered on your insurance. (17:33) It didn't matter if you had diabetes. (17:35) You could just take that to the pharmacy and get Mounjaro for $25. (17:38) And then, of course, they, you know, cut that off like a sieve once the word started to get out about how powerful tirzepatide, the active ingredient in Mounjaro, is at getting people's weight down.
David Knapp (17:49) They had to pull back on the savings card because it became so popular so fast with, mind you, zero advertising. (17:55) Right. (17:55) It was all word-of-mouth. (17:57) These drugs went into shortage. (17:58) And so very quickly, you being in the type one world, like, I know these companies manufacture insulin all day in little single dose or multidose vials.
David Knapp (18:07) Why can't they just do that? (18:08) And so I actually started a social media campaign that went viral and ended up getting covered by some of the major news outlets called Release the Vials, which ultimately, through conversations with Lilly, actually had conversations with their, CEO there, they ended up releasing Zepbound in single dose files and going direct to consumers with the cash pay price, and they were kind of the first ones to do that even before this most favored nation stuff with the with the administration.
Scott Benner (18:34) Yeah. (18:34) That's really interesting. (18:36) The things that I've seen it help people with, I really hope that we can get to a point like, I'm not listen. (18:41) I'm not confused. (18:42) I'll actually, let me share this with you, then I'll go backwards.
Scott Benner (18:45) Fifteen years my wife works in, drug safety. (18:47) Okay. (18:48) So she does kinda like the behind the scenes pharma stuff where she makes sure that, you know, reporting's done correctly and that, you know, things are being done the way they're supposed to, that kind of stuff. (18:56) Right? (18:57) She came home to me fifteen years ago, and she goes, Scott, one day, people are gonna take an injection, and they're gonna lose weight.
Scott Benner (19:03) And I was like, what do you mean? (19:05) She goes, I saw some data, and she's like, we're working on this type two drug, and she was at Novo. (19:10) But, man, like, you should see the data on people losing weight. (19:14) I really think one day people are gonna take a shot and lose weight. (19:16) Three years ago now, maybe coming up on three years ago, I started doing it.
Scott Benner (19:20) I was like, oh my god. (19:21) This is the thing Kelly was talking about. (19:22) And just like that, it it started to happen. (19:24) Now, of course, before before that, they but they had other JLPs. (19:27) Right?
Scott Benner (19:27) Like Rybelsus and there were, like, pills and stuff like that. (19:30) Didn't really work quite as well. (19:31) But now I'm seeing it help people in, like, such varied ways. (19:35) I mean, no kidding. (19:37) All the different ways that you see it impacting lives that I can see it impacting my life.
Scott Benner (19:42) You know, we talk so much about, like, trying to fix things for people. (19:46) Like, they just ate better. (19:47) If, you know, there's Mhmm. (19:48) No factory farming. (19:50) If they and you start piling up all these if if if if, and you realize, like, we're not getting any of this straight.
Scott Benner (19:54) Right? (19:55) Right. (19:55) People keep suffering, and they keep gaining weight, and they keep being ill, and they keep, you know, just not having the lives they can. (20:02) I'm not a person who's, put everybody on medication. (20:04) I'm really not.
Scott Benner (20:05) But, like, now that I've seen what it's done for me, I'm not down with just yelling like you're cheating if you're doing this thing. (20:12) Like, right like, I don't know why my body doesn't work the way it's supposed to, but it clearly doesn't. (20:18) And you add this GLP to me, and I'm better off. (20:22) I don't like, when people say to me, oh, you're have to use it for the rest of your life? (20:25) I'm like, whatever.
Scott Benner (20:26) I was like, because the other way, was gonna have a heart attack for sure. (20:28) So Right. (20:29) You know, whatever. (20:30) And now you're talking about that pill. (20:31) That pill might end up being more of a maintenance thing for someone like me.
Scott Benner (20:34) Right? (20:36) I used to hate ordering my daughter's diabetes supplies. (20:40) I never had a good experience and it was frustrating. (20:43) But it hasn't been that way for a while. (20:45) Actually, for about three years now because that's how long we've been using US Med.
Scott Benner (20:51) Usmed.com/juicebox or call (888) 721-1514. (20:59) US Med is the number one distributor for Freestyle Libre systems nationwide. (21:05) They are the number one specialty distributor for Omnipod Dash, the number one fastest growing tandem distributor nationwide, the number one rated distributor in Dexcom customer satisfaction surveys. (21:16) They have served over one million people with diabetes since 1996, and they always provide ninety days worth of supplies and fast and free shipping. (21:26) US Med carries everything from insulin pumps and diabetes testing supplies to the latest CGMs, like the Libre three and Dexcom g seven.
Scott Benner (21:37) They accept Medicare nationwide and over 800 private insurers. (21:42) Find out why US Med has an a plus rating with the Better Business Bureau at usmed.com/juicebox, or just call them at (888) 721-1514. (21:54) Get started right now, and you'll be getting your supplies the same way we do.
David Knapp (21:59) It sounds like the pills may be a great option for maintenance. (22:01) For people with, let's say, less severe metabolic disease, they're not gonna be as potent, to start with. (22:07) They're not gonna be as potent as the injectables. (22:10) They kinda tout that these high doses of so high dose Rybelsus, which is the oral semaglutide from Novo Nordisk for diabetes, is currently with the FDA for approval in high doses for what they're calling oral Wegovy, which is their injectable weight loss medication, their popular one. (22:27) They are touting that those get up there, but still, I think most people are gonna tolerate the shots, once weekly shots, better.
David Knapp (22:34) But, yeah, for maintenance, there's a whole lot of hosts and applications for these oral versions, and maintenance is definitely one big thing that they're looking at. (22:43) But one of the things I want to touch on based upon kind of what you were just saying there, because I think you hit on something that I think is what needs to be understood. (22:50) When we talk about the discourse, the public discourse around GLP one medications and this idea of taking a drug forever or or cheating or taking the easy way out, I just wanna kinda reframe that conversation for people and just kinda build on what you were saying there is we can all agree that there are likely contributing factors, confounding factors in this country specifically that contribute to metabolic disease that are beyond just your own personal agency. (23:18) Right? (23:19) Sure.
David Knapp (23:19) We don't know how what they're spraying on our crops affects our gut microbiome. (23:24) We don't know really how much or how little the prescription drugs that we're taking, we're learning more, are screwing with our gut microbiome. (23:33) We don't know how how much, for instance, alcohol screws with our gut microbiome. (23:38) What they're finding right now, we're gonna get data later this week, probably, maybe early next week from Novo Nordisk that's likely to show that Rybelsus slows the progression of Alzheimer's. (23:49) Why is that?
David Knapp (23:50) Because they have found this gut brain connection that they're just now starting to unwind. (23:55) But these GLP one medications, all they are are manufactured peptides that, in Inovo's case, they actually make it from yeast. (24:05) They're peptides that mimic hormones that are naturally made in your gut. (24:10) But there's byproducts of gut bacteria. (24:13) There's byproducts of adipose tissue called d p p four that literally is run amok in the guts of people who are diabetic and obese.
David Knapp (24:23) They've done studies on this. (24:24) It's this d p p four enzyme that destroys GLP-one, native GLP-one or endogenous GLP-one, GIP, these incretin hormones. (24:35) Right? (24:35) And so a lot of what they're learning is is this unique connection between the gut and the brain in terms of signaling satiety, signaling insulin release. (24:46) And these hormones are integral to that.
David Knapp (24:48) And you can imagine what's happening in the guts of people who have had their good bacteria destroyed or have high adiposity where the environment there is working against your own native GLP one. (25:00) That's one of the reasons that these medications work so well is prior to GLP one medications, there was a whole another class of type two diabetes medications called DPP four inhibitors. (25:10) So that culprit that attacks your endogenous GLP-one, your endogenous the Ozempic that your body makes naturally, essentially, they had a drug that tried to block that DPP-four so that your native GLP-one could shine through and do its job, signal to satiety, signal insulin release, stimulate the beta cells in your pancreas to release insulin more efficiently, etcetera. (25:34) And so these medications are literally and this is sort of one of the more controversial things that I'll say is that I believe they are the antidote to whatever the culprit is, and it's probably many factors that are creating a hormonally dysregulated body for people who are metabolically sick.
Scott Benner (25:54) Yeah. (25:54) I don't know another way to explain it to you other than my body just works better now. (25:58) And, I mean, from, like I used to have terrible reflux. (26:02) Gone. (26:03) Had it, like, most of my life.
Scott Benner (26:04) It's just gone. (26:04) People will say, what's because you lost weight? (26:07) It was gone before I lost the weight. (26:09) I used to be anemic all the time. (26:11) Like, I'm telling you, Dave, like, I would I was in the last handful of years of my life, I was getting two and sometimes three iron infusions a year so that my ferritin wouldn't drop off the planet.
Scott Benner (26:22) And I and I I couldn't, like, I couldn't stand some days. (26:25) Like, I was so anemic. (26:26) I haven't been anemic in almost three years. (26:29) What happened? (26:29) My expectation is my digestion changed.
Scott Benner (26:32) My body is now picking up nutrients differently, and I'm not lacking in iron anymore. (26:37) That's a simple thing that to your bigger point about, like, I'm sure there's a million things happening that are impacting us that we don't know about. (26:44) I wasn't gonna unwind all that in my lifetime. (26:47) Right? (26:47) And even if I could, what am I gonna go live in a yurt?
Scott Benner (26:51) Like, you know what I mean? (26:51) Like, grow a carrot in my own like, don't know. (26:54) What was I gonna do exactly? (26:55) Right? (26:56) You're like, like, I got a house.
Scott Benner (26:57) I got kids. (26:57) I gotta live my life. (26:58) This is the world I'm in right now. (27:00) If the world's doing this to me, then and there's an anecdote, you know, quote unquote to that. (27:05) I'm in.
Scott Benner (27:06) Like, I'm in to take it because I wasn't gonna live as long. (27:09) I wasn't my days were much less pleasant. (27:11) I was never rested. (27:12) The reflux gave me, other issues that I'm hoping don't turn into bigger problems. (27:17) Right?
Scott Benner (27:18) Like Right. (27:18) There's a lot going on. (27:20) And now all of a sudden, man, I'm full of energy. (27:22) I got nothing but, like, clarity in my mind. (27:25) Like, you know, I've worn a CGM a couple of times.
Scott Benner (27:28) My glucose doesn't move. (27:30) Like, you almost can't will it to move. (27:31) Yeah. (27:31) It's been so beneficial. (27:33) And then we were able to you know, like, I think I told you before we started talking, I used it.
Scott Benner (27:38) My wife used it. (27:40) Awesome results. (27:41) My brother has type two. (27:43) I'm adopted, so not my brother by blood. (27:45) But my brother, type two diabetes, he's lost, like, 70 pounds.
Scott Benner (27:48) His a one c's dropped way down, like, two points down. (27:51) And still, he was with a doctor the other day who said to him, if I was you, I wouldn't be using this GLP medication. (27:57) Awesome, man. (27:58) Thanks. (27:58) How come?
Scott Benner (27:59) Muscle. (28:00) He kinda waved his hand at him. (28:01) I mean, muscle wasting. (28:02) And I was like, Brian, I'm like, GLPs don't magically make muscle go away. (28:06) I'm like, they can give you like, put you in situations that can cause that, and there's ways to counteract that.
Scott Benner (28:11) I was like, he's like, don't worry. (28:12) I'm not gonna stop taking this. (28:13) And I was like, oh, okay. (28:14) But, like, it's amazing that, like, in 2025 now, there's still a doctor who's just, like, waving their hand randomly saying muscle out loud and telling a guy whose a one c went from the sevens to the fives and lost 70 pounds, hey, you probably shouldn't be taking that. (28:27) So that guy doesn't understand this functionally at all.
Scott Benner (28:29) No. (28:29) And he's out there giving advice. (28:31) So in a world where there are doctors giving advice that they don't know about, that, like you said, something's getting sprayed on something. (28:37) I'm eating it. (28:38) Something in my stomach that medicine barely understands at this point
David Knapp (28:42) Right.
Scott Benner (28:42) Is getting dysregulated. (28:44) Who cares, man? (28:45) Like, do you know what I tell people? (28:46) I have a GLP deficiency. (28:48) That's what I tell them because it shuts them up.
Scott Benner (28:50) And like and I don't really know what else to say.
David Knapp (28:52) I love it.
Scott Benner (28:54) So when you see it back into this world a little bit with type one, I know this isn't, you know, your what your focus is on, but I feel like you might have a lot of information that's gonna help otherwise. (29:03) So if you don't have an answer, just say, Scott, I don't know. (29:05) This isn't my this isn't my lane. (29:07) But when people talk about GLPs reducing inflammation, for example, do you understand or does anyone understand how that happens, or do we just know it does happen?
David Knapp (29:17) I believe they're trying to untangle untangle all of that and why it works too, especially on that inflammation. (29:26) I know that with tirzepatide, they're doing some studies that are looking at, the c reactive protein, which is one of the biggest markers for inflammation in the body. (29:35) They're seeing reduction in all of those. (29:36) And and in fact, the next sort of advent of where GLP ones can take us because, honestly, they're gonna have the weight problem solved in the next ten years. (29:47) There's not gonna be there's gonna be something for everyone, I firmly believe, out there that's gonna get you to your goal weight more than likely.
David Knapp (29:54) The question now becomes, a, how do we improve the quality of weight to the doctor's point of muscle wasting, which that happens when you lose weight dramatically. (30:03) I mean, these
Scott Benner (30:03) Yeah.
David Knapp (30:04) Medications, the ones that are on the market currently, essentially help bring down your weight by reducing the amount of energy you put into your body. (30:11) And so if you're reducing the energy you put in, that's how you get weight loss. (30:15) But, unfortunately, with weight loss, you're losing a certain amount of muscle mass. (30:20) So the quality of weight loss is what they're looking at in the future pipeline of these medications, but they're also looking at other indications because there's people like you who walk around and say, you know, actually, this is how it helped me. (30:33) I, you know, I have rheumatoid arthritis, and all of a sudden, I don't need my rheumatoid arthritis medication, or I have, you know, irritable bowel syndrome, and it's cleared up.
David Knapp (30:42) Like, all these things that that really at the heart of it, you know, are inflammatory drivers Mhmm. (30:47) In the body. (30:48) And then so they're looking at that, and they're looking at combining these medications with other treatments for some of those autoimmune dis diseases. (30:56) So autoimmune diseases are kind of the next frontier of where they're looking specifically with tirzepatide, because one of the things we call these medications is GLP-one medications. (31:06) But at the end of the day, everything up until tirzepatide, which is Mounjaro and Zepbound, was just a GLP.
David Knapp (31:13) Mounjaro tirzepatide, the active ingredient, is actually two hormones in the family of they're called incretins. (31:20) They're nutrient stimulated hormones. (31:22) In other words, you eat food and your body releases these. (31:25) When your gut starts to sense the nutrients, it releases these hormones naturally. (31:29) GIP is another prominent one.
David Knapp (31:31) It's actually I think they discovered GIP before they discovered GLP one, but it's a combination of both. (31:36) And it's mostly a GIP medicine with just a little bit of GLP-one where like Ozempic semaglutide is just straight GLP-one. (31:44) Not super important, but for the purposes of what you're talking about with inflammation, what they're finding is that profound effect on inflammation in maybe some ways that GLP-one doesn't. (31:56) These molecules have protective properties in the body that they're just starting to understand, and and these properties are independent of weight loss. (32:04) Mhmm.
David Knapp (32:05) So for example, one of my favorite pieces of data on semaglutide, which is, you know, becoming kind of like an old school drug. (32:14) And when you talk about Ozempic, they're like, hey. (32:15) Have you heard of Mounjaro? (32:17) It's even better. (32:18) But when you look at GLP one receptor agonism, in the biggest study for semaglutide, which was called the SELECT trials in cardiac stuff.
David Knapp (32:27) Right? (32:27) So it was looking at people with heart failure, and then it was looking at major cardiovascular outcomes. (32:33) In this trial, there was some tens of thousands of people were enrolled in this trial, and it it lasted for four years. (32:40) And what they found was it didn't matter what dose of semaglutide you took, and it didn't matter how much or if you lost weight. (32:49) You experienced a twenty percent reduction in major cardiovascular events, a twenty percent reduction in deaths associated with major cardiovascular events.
David Knapp (32:59) And so what they thought in that trial or one of the things they're extrapolating was there's something specifically protective in the heart about the GLP one molecule. (33:10) And so they they spun off researchers spun off a smaller study that just came out a couple weeks ago, and this is just in rodents. (33:17) But what they did is they took the first GLP one that ever came out. (33:21) It's called Byetta. (33:22) Mhmm.
David Knapp (33:22) Really cool story about how they discovered that one because in the nineteen sixties, and May maybe it was the seventies, they discovered this thing called the incretin effect. (33:31) We call these the incretin drugs. (33:33) Right? (33:34) They discovered that, hey. (33:35) When you inject somebody with glucose and when you feed somebody with glucose, there's actually a quicker metabolic response when you feed it to people, and they ingest it through their stomach and their gut rather than injecting it.
David Knapp (33:48) And they called this the incretin effect. (33:49) That's because these hormones, like I said, are nutrient stimulated, but they lack the ability to, you know, create duplicate peptides of ones that were already in your body. (33:59) And so through research, these doctors were looking at the venom of Gila monsters because they found that it lowered blood sugar, and then they isolated a peptide in the venom of a Gila monster and found that it nearly mimicked exactly human GLP one. (34:16) Mhmm. (34:16) Except instead of lasting for just a few minutes in the body and getting destroyed by d p p four, they could make it last for four hours.
David Knapp (34:24) Right? (34:24) So that's that's how they came up with the first GLP one. (34:26) So this study with the rodents actually looked at exenatide, which is the first GLP one. (34:30) They basically gave it to these rodents and induced a heart attack. (34:34) And there were two subsets of these rodents.
David Knapp (34:36) There were the kind that got the GLP one, and then there were the kind that actually got a version of the exenatide that actually blocks the GLP one receptors. (34:43) And so there's these cells on the hearts. (34:45) They're called parasites. (34:47) They found that the rodent population that got GLP one receptor agonism injected into them along with the heart attack, it opened up the blood flow to the part of the heart that otherwise would have been damaged permanently. (35:01) And conversely, in the rodents that didn't, that got the GLP one blocker, that part of the heart stayed forever damaged.
David Knapp (35:08) It never got the blood restored to it. (35:10) So long way around saying that there's something that's protective about these molecules themselves independent of the weight loss. (35:17) Mhmm. (35:18) And to our earlier points, there's something within our ecosystem here that has caused dysregulation in these hormones, and I believe that's why you're seeing people that get on these medications, even ones that don't have, like, a tremendous amount of weight to lose and maybe even none, and they're just microdosing because they've read the studies and they wanna get some of these benefits that they're saying, you know, my my psoriasis is going away. (35:44) My arthritis is getting better.
David Knapp (35:47) My I mean, fill in the blank. (35:49) There's so many things.
Scott Benner (35:51) I haven't had an eczema flare in years. (35:54) Wow. (35:54) I used to have it every it just occurred to me as you're saying it. (35:58) Like, this time of year, it starts to get colder, I would get these red patches on the inside of my thighs and sometimes in the back of my arms, and I haven't had them in years. (36:06) No.
Scott Benner (36:06) No kidding. (36:07) Yeah. (36:07) Yeah. (36:08) Yeah. (36:08) Yeah.
Scott Benner (36:08) I I just heard you say I'm gonna live forever, Dave. (36:10) Thank you.
David Knapp (36:11) Appreciate yeah. (36:11) Yeah. (36:13) That is that's what I was getting at.
Scott Benner (36:14) I only got plans for the next twenty years. (36:16) I'll have to figure something else out. (36:18) It's interesting. (36:19) You're younger than me. (36:21) But and it's really let me say before I say this.
Scott Benner (36:24) It's really interesting talking to you. (36:25) What did you do before this professionally?
David Knapp (36:28) I sold traffic signals.
Scott Benner (36:29) That's amazing, man. (36:30) It's
David Knapp (36:30) a It's natural transition.
Scott Benner (36:32) Yeah. (36:32) I mean, I just I love that when you're talking about it, I'd be thrilled if my doctor understood this as well as you did. (36:37) Like, you you know what I mean? (36:38) Like, it's so cool. (36:39) I brought this up in the beginning, but it it so kinda mimics me a little bit.
Scott Benner (36:43) Like, I I'm not perfect. (36:45) I don't know everything, but I try learning all the time. (36:47) And what this job allows me to do is it allows me to be steeped in it constantly. (36:51) Yeah. (36:51) And I think we need more people who just spend a lot of time in an idea absorbing it, you know?
Scott Benner (36:56) So very cool that you're doing this and that you can speak about it so well.
David Knapp (36:59) Appreciate that.
Scott Benner (37:00) But what I was saying is, like, when I was growing up, I've said this before on here, all the time, like, biggest problem people had was their weight. (37:06) Like, oh my god. (37:07) If medicine would just figure out weight, if they would just figure out weight, like, the the society just wanted it. (37:11) They begged for it. (37:12) And then we gave it to them and people like, you're a cheater.
Scott Benner (37:14) And I'm like, oh my god. (37:15) People are fickle. (37:16) Fascinating. (37:16) But okay. (37:17) We get past that.
Scott Benner (37:18) The other thing I've been hearing about
David Knapp (37:19) weight down, but not that way.
Scott Benner (37:20) Not like that. (37:21) Do it the way you're supposed to.
David Knapp (37:22) Like, Jack And there's also, like, what drives me insane is there's also an assumption that people are just taking the medicine, and they're not also going to the gym. (37:32) They're not also watching what they eat. (37:34) Like, these medicines don't just magically work for everyone. (37:39) Most of the people we have a 160,000 people in the OTP community across the platforms. (37:44) And there are very few people, if any, that I've met that are like, I just let the drug do the work.
David Knapp (37:50) They're all in the gym.
Scott Benner (37:51) Also, wanna say, if that's what they did, like, god, like, it's their life. (37:54) Like, you know what I mean? (37:55) Like, if they're better off, let them be better off. (37:57) My point about the the weight is we talk all that's all society talks about. (38:00) We gotta help people with their weight.
Scott Benner (38:02) And the other thing I hear people talking about my whole life is inflammation. (38:05) Inflammation's such a problem. (38:07) It's such a problem. (38:07) We can't and I believe it, by the way. (38:09) Like, you can't take an NSAID every five minutes.
Scott Benner (38:11) But, you know, you've had issues. (38:12) You take an Advil. (38:13) It reduces the inflammation in your body. (38:15) You're like, oh, this is better now.
David Knapp (38:16) Right.
Scott Benner (38:16) Some people have it more chronically. (38:19) You know, I watch my daughter who obviously has, you know, an autoimmune issue, but she also has like, she has hypothyroidism. (38:26) She has type one diabetes. (38:28) She might have PCOS. (38:29) And I'm telling you that when she's on this medication, things are better for her.
Scott Benner (38:34) Mhmm. (38:34) Like, they they just are. (38:35) And I have a giant community of people who are reporting back very similar, you know, returns. (38:40) And they're a little blocked because, of course, in the studies, they found that, you know, people with type one diabetes were going to DKA sometimes. (38:50) And it's but it's really I think it turns out to be just because they eat less and they're using less insulin, and then they ended up in DKA because they type one and they need insulin and they weren't using enough.
Scott Benner (38:59) They didn't have their settings changed. (39:01) Because with my daughter, I've never had that problem. (39:03) When she's using the GLP, you just have to titrate back her basal. (39:07) You'd be surprised how much of her, how how wide her settings can swing. (39:11) Without a GLP, it could take one unit of insulin to move my daughter's blood sugar 34 points.
Scott Benner (39:18) But on a micro dose of GLP, one unit of insulin will move her blood sugar 95 points. (39:25) That's insane. (39:26) Right? (39:26) Like, she she's in involved in some sort of insulin resistance or inflammation or I don't even care. (39:32) Like, I genuinely don't even care what you call it.
Scott Benner (39:34) It doesn't matter to me. (39:35) Like, I see I see what happens. (39:37) Then I talk to other people who are having other, you know, issues. (39:41) And then everybody that comes on here, you know, you didn't start this way, but if you came on and you had type one, I'd say, hey. (39:47) Do you have any other autoimmune issues?
Scott Benner (39:48) How about in your family? (39:49) And people sit down. (39:50) They go, oh, I got celiac. (39:52) You know, there's vitiligo. (39:53) I have a friend of mine who's got eczema.
Scott Benner (39:55) There's a lot of a lot of allergies, hypothyroidism. (39:58) Like, they these it it runs through their family lines. (40:01) And I just imagine and believe that these people are experiencing a higher level of inflammation, like, just generally speaking. (40:08) Like, so if if this leads to, I don't know, ten years from now, them coming out with something else that just lowers people's inflammation a little bit, I think I think this is awesome. (40:19) Like, what was I seeing the other day?
Scott Benner (40:21) My brother got I was my brother was sick. (40:23) I told you. (40:24) And, he's got a virus. (40:25) It's just not passing quickly, and so they put him on a steroid pack. (40:29) But by the way, like, he had to beat him over the head to even get the steroids.
Scott Benner (40:33) Like, that won't help you. (40:34) Like, you know, arguing with him. (40:35) He finally gets the steroid pack. (40:37) He's on the steroids for a couple hours. (40:38) He calls me because, Scott, I feel so much better.
Scott Benner (40:40) Like, the all the pain's going away, blah blah blah. (40:42) And I I said to him, did you know that in the forties when steroids became you know, when they figured them out they started using them for a split second, they thought they had literally fixed all the problems mankind had. (40:55) And and until you realize what happens if you stay on these steroid packs too long and you get rebound and it's it's not great. (41:01) Right? (41:01) There's a lot of problems if you stay on them too long.
Scott Benner (41:03) But still, when you're on them in that short window I don't know if you've ever experienced this. (41:08) I feel like Superman when I'm on a steroid pack. (41:10) I'm almost excited when I'm sick. (41:11) I'm like, my god. (41:12) They're gonna give me a steroid pack.
Scott Benner (41:13) Next week of my life's gonna be awesome. (41:15) Man, imagine that. (41:16) Like, imagine if this stuff leads to not just people losing weight, people's a one c's dropping out of a diabetic range, type ones hopefully needing less insulin, people with autoimmune having less impacts from their autoimmune issues, and what if they could get rid of, like, some of this inflammation for people?
David Knapp (41:32) Absolutely. (41:33) I I one of the things that I've been saying for a couple years too that has been, you know, one of the more controversial things in terms of just the feedback that I get from people is I really believe these medications, these these incretin nutrient stimulated hormones, however you wanna couch them. (41:48) We'll call them GLP ones because that's what everybody else does. (41:51) But I believe they have the power to save our health care system in The United States. (41:54) And when this new administration came in, there was a lot of people who were very nervous within our community about how they were going to treat GLP ones because there was a lot of, like, anti Ozempic talk before they came in.
David Knapp (42:06) And I was just, like, hoping beyond hope that once they got in and really looked at the data objectively and maybe, you know, took their political hats off and put on their their data hats, that they would see what we have been seeing in this community for so long that that these medications really have the power at the right price to transform the health in this country. (42:29) Because, again, you know, we have the these drugs have been out for a long time. (42:33) That's another, like, misnomer that people have is that they're brand new. (42:36) They're not. (42:37) The Dyetta's been around for twenty years.
David Knapp (42:39) Mhmm. (42:39) And so we have lots of years of data with these drugs on the market to that we can go back and comb. (42:45) I don't know how much your audience gets in the weeds on, like, clinical trial data, but they have these these studies called post marketing studies. (42:52) So you have phase one to make sure that, you know, animals don't die when you inject them with something. (42:58) Right.
David Knapp (42:58) And then they put them in phase two small two, like, small human trials. (43:01) And then phase three is the last one before it gets approved, the bigger trials to figure out dosing and etcetera. (43:08) Well, they have these phase four trials once something comes to market where they're able to just aggregate data. (43:13) Right? (43:14) All these patient records and say, here's these 20,000,000 people that are on GLP ones.
David Knapp (43:19) What they're seeing in almost every single major medicine journal has showed lower CRP, lower IL six, lower TNF alpha. (43:27) What these are doing to fatty liver disease and metabolic health directly by mechanisms of of reducing liver fat and even reversing fibrosis stages, What they're showing is that, like, can you imagine the downstream effects? (43:41) Even just the twenty percent reduction of major cardiovascular events with semaglutide, you know, and the reduction in hospitalization. (43:48) So I don't think it can be understated what just happened last week, or maybe it's a couple weeks now, with the administration getting the pharmaceutical drug companies to the table and saying, hey. (44:00) Like, let's work on volume here.
David Knapp (44:02) Every almost my own personal held belief that almost everyone who lives in this country should be considering the idea of talking to their doctor about whether a medicate one of these medications could benefit them in some way.
Scott Benner (44:16) Dave, gotta tell you. (44:17) I think for a minute, people thought, like, that Lily and and Nova were sending money over here because I was like, let's spray it out on airplanes.
David Knapp (44:24) Mhmm.
Scott Benner (44:25) You're seeing, like, so many people. (44:27) You you know what I realized when I talk to people over and over again? (44:30) And this is interesting. (44:31) Right? (44:31) Is that I don't think people think they're eating poorly.
Scott Benner (44:34) Like, I think when you really like, it's it's easy to step back and, like, say, oh, like, poo poo. (44:40) People don't take good care of themselves or, like, you know, you you act like those bro podcasters, like, who's gonna row the boat, all that stuff. (44:45) Like, you know what mean? (44:46) Like, I I it's easy to say work harder, do better. (44:49) Like, you know, the last thing I need is a guy making $20,000,000 a year telling me I got a cold plunge in the morning.
Scott Benner (44:54) I'm like, I'm at work. (44:55) Like, I don't Right. (44:55) Get it, like, thanks. (44:56) Big help, man. (44:57) Thank you.
David Knapp (44:58) Right. (44:58) Right.
Scott Benner (44:58) But when I look at people, I don't think people are out there doing a poor job on purpose. (45:02) And I think, moreover, I don't think they know they are if they are. (45:05) Right. (45:06) Around nutrition, around other health issues. (45:08) I talk to people all the time.
Scott Benner (45:10) They're not like, oh, you know, I know I'm making bad decisions all day long. (45:14) You know, I have extra money to buy better food, but I just decided to buy crack with it instead. (45:19) Like like, people are doing their best in the system that they have, in the life that they have. (45:24) No one wants to be unhealthy. (45:25) Like, I find Right.
Scott Benner (45:26) Like, calling people there's a thing they do in type one, is if you don't have the outcomes that the doctors want, they tell you that you're noncompliant. (45:34) Yeah. (45:34) We told you what to do and you're not complying. (45:36) I talk to people all the time. (45:37) I don't find people to be noncompliant at all.
Scott Benner (45:39) They're trying as hard as they can with their understanding and their tools and their finances insurance and all the other things that they have and their time, by the way, Dave. (45:47) Because they get up in the morning and they got kids and they got a vacuum and they gotta go to school and they gotta go to work and, like, nobody's got time to sit and talk about this shit like we do. (45:55) Like, right? (45:55) Like, you know, so telling people do better, and then when they don't do better, go, well, you must not be trying hard enough. (46:02) I guess you deserve to die.
Scott Benner (46:03) What a bizarre thing to do to people. (46:05) And we're out here saying there's not enough food for people. (46:08) We can't do small farming because we have to make food for so many people. (46:12) You know how much less food I eat now? (46:13) I'm fine.
Scott Benner (46:14) You know what I mean? (46:15) Like, I don't eat, like, in bulk the way I used to. (46:18) You can't even. (46:19) I mean, you ever go out my wife and I go out the other sometimes we order a dish and we split it. (46:23) We still and we still don't fit it.
Scott Benner (46:25) And we're nice and full and healthy and everything's okay. (46:27) My point is that if there's all this inflammation and all this autoimmune and all this weight and all the other things that are impacting people, I want those people to open their minds up more. (46:38) Like, this is what I I you know, at the pharma level, at the doctor's level, like, look listen to what people are saying and look at your patients and say, like, could I be helping them with this? (46:49) Right? (46:49) Like, do I want the world to be fixed another way?
Scott Benner (46:52) Like, should Monsanto not spray whatever they spray on my wheat? (46:55) Like, yeah. (46:55) Awesome. (46:56) I don't how to impact that. (46:57) Mhmm.
Scott Benner (46:57) You know? (46:58) But on my side, I know what's working for me. (47:01) And, honestly, I don't even understand if trust me. (47:04) I'm making this up right now. (47:06) I wish they'd mix it into the insulin.
Scott Benner (47:08) I heard you
David Knapp (47:08) talk They are, by the way. (47:10) Yeah. (47:11) Like, Novo Nordisk and Neon Lily, I think both have clinical trials combining GLP with insulin.
Scott Benner (47:17) Dave, you don't know me well. (47:18) I'm gonna cry. (47:20) It's fucking awesome, man. (47:21) My daughter has a needle phobia. (47:23) She's a lot of trouble taking the GLPs.
Scott Benner (47:26) I sit in here and I I stare at it and I wonder, like, I would never I wanna be clear. (47:30) I wouldn't do this. (47:32) But, like, there's this little part of me that wants to just squirt some of the GLP into the insulin because it'll go into her pump and help her. (47:37) I know by trust me. (47:38) Don't do that.
Scott Benner (47:38) That's not what I'm saying. (47:39) What I'm saying is is that, like, I just I'm like, god. (47:42) Why can't they just do that a little bit? (47:44) Like, look what it does for her. (47:45) Like, how much less insulin would she need?
Scott Benner (47:48) Because also the dosing is all screwy. (47:50) Yeah. (47:50) Probably you can explain it to me better, but, like, the dosing, the way the pens are set up. (47:55) Right? (47:55) Like, it's just it's what testing what told them would work.
Scott Benner (47:59) Right? (47:59) If they spread it over the population, like Right. (48:01) Most people will have some success at this. (48:03) But there are plenty of people who do two and a half, and they go, oh, it made me nauseous. (48:07) I couldn't keep doing it.
Scott Benner (48:08) But one and a quarter might have been perfect for them. (48:11) Mhmm. (48:11) I'm saying, like, open up the dosing to people.
David Knapp (48:14) Oh, yeah.
Scott Benner (48:14) Yeah. (48:15) Let them make their own decisions about how much they get.
David Knapp (48:17) I think one of the cool things that has happened unintentionally, like an unintentional consequence of those really early shortages of these medications, was that it opened up the world of compound medications and personalized medication. (48:32) I don't know how much you get into the compound world over here. (48:35) But really, essentially, a quick flyover is in this country, when a drug comes to market that's not a biologic, if the manufacturer can't keep up, we have this system called compound pharmacies, 503A and 503B compound pharmacies, that can basically step in and make and sell to doctors who prescribe them to patients drugs that are in shortage. (48:58) So you sort of bypass the intellectual property at that point. (49:02) Mhmm.
David Knapp (49:02) One of the interesting things that's happened is it spurred this whole telehealth world where doctors are prescribing GLPs on a personal level, and they're actually prescribing microdose versions of these drugs. (49:15) Because, again, we're never gonna get a trial clinical trials are are designed by the pharmaceutical companies.
Scott Benner (49:21) Yeah.
David Knapp (49:22) They want you taking more of their drugs. (49:24) So first of all, just know that about a clinical trial is that it's funded by the pharmaceutical companies that run them. (49:31) Mhmm. (49:32) But second of all, when you look at what they're trying to accomplish in a clinical trial, especially for obesity and diabetes, is they're if in diabetes, they're looking at a one c type two diabetes. (49:44) They're looking at a one c reduction.
David Knapp (49:46) And in obesity and I'm talking about this because this is my world, though type one world isn't the world that I live in. (49:52) In obesity, they're just trying to slam you with as much medicine as possible to balance side effects and get the maximum amount of weight loss because that's what Wall Street wants. (50:02) And so, really, clinical trials are designed less they're designed for regulators, and they're designed for investors. (50:10) They're not really designed for patients, and we're starting to see a shift in that. (50:13) But because the shortages led to this world of compounding, you have now millions of people who have gotten benefits of the benefits of getting on a individualized dose of these medications and finding that 2.5 of tirzepatide is the starting dose commercially.
David Knapp (50:32) But I, I just being a figurative random person, took 10% of that a week and got similar benefits. (50:40) Mhmm. (50:41) You know? (50:41) And so we're seeing in real in the real world this sort of situation play out where we're starting to see, like, a massive sort of nontraditional clinical trial going on showing that these these peptides specifically have benefit for a lot of people outside of the normal dosing that we got from the clinical trials, including, but not limited to, microdosing. (51:06) And I
Scott Benner (51:08) The way I see with my daughter and with myself so I first learned it with myself is that I'm sure most people who use these drugs will tell you this. (51:16) I'm on Zepbound. (51:17) I I do twelve and a half. (51:18) Right? (51:18) Okay.
Scott Benner (51:19) I shoot it usually on Saturdays or Sundays. (51:22) By Thursday, I start thinking about, like, maybe I should order a pizza tonight. (51:26) Like right? (51:27) Like, on Wednesday, I'd never think that. (51:28) On Friday, I actually could get a pizza.
Scott Benner (51:31) I can only eat a slice of it or so, but, like, the whole process like, I can feel it let go of my brain a little bit. (51:37) Like, I don't know if another way to put this unless you've been on these. (51:39) Like, the best way I can explain it to people is that my brain doesn't tell me I'm hungry, and my stomach doesn't tell me I'm hungry. (51:44) Like, like, I if I don't I need to remind myself to eat. (51:48) It was tough to do in the beginning, by the I used to I set alarms in the beginning.
Scott Benner (51:52) Like, have breakfast now. (51:53) Eat this. (51:53) Make sure you have protein, like, that kind of stuff. (51:56) But then I said, okay. (51:57) So, obviously, the life of this drug in my body, it wanes.
Scott Benner (52:00) It's not completely gone, but it wanes. (52:03) Even I could see, like, weight loss first four days, and it maybe drifts back a little bit in the last three days and everything. (52:08) Yep. (52:08) So I'm looking at my daughter. (52:10) And, the issue is with her not wanting to do the injections.
Scott Benner (52:13) But, you know, we started with a a 2.5 Mounjaro pen for her. (52:18) Because, by the way, my daughter has a a dual diagnosis. (52:20) She has a type one diagnosis and an insulin resistance diagnosis, so she gets Mounjaro through her insurance. (52:25) Two and a half's too much. (52:27) She'll lose too much weight.
Scott Benner (52:28) She's never hungry. (52:29) It's not it's way too much for her. (52:31) But you can argue with the fact that her a one c is, like, 5.2, and her blood sugar won't spike over, like, one fifty, like, no matter what she's eating. (52:39) Right? (52:39) Yep.
Scott Benner (52:40) Even if she can you know, she talked herself into eating through not being hungry. (52:43) And so one day, I'm like, this is not sustainable. (52:46) And so I learned about microdosing, bought some vials on Amazon, injected the pen into the vial. (52:53) I basically I didn't know how much was in there, so I drew it all out, and I and I converted it to insulin units, basically, because I had insulin needles. (53:00) And I'm like, alright.
Scott Benner (53:00) Well, there's this many units in here. (53:03) The whole of it is too much. (53:04) I'll try giving her half. (53:06) And then every week, I'd try giving her, like, an insulin unit less and and trying to look for a sweet spot where she could get a week's worth of coverage on her insulin resistance and her insulin usage. (53:16) But the truth is it should probably be shot even less than that, like, every four or five days because of the the life of it.
Scott Benner (53:24) Yeah. (53:25) It's a struggle, man. (53:26) You should see. (53:26) Like, it's I know it's a weird thing to say that a type one is, like you know, has, like, a visceral fear of injections, but she does.
David Knapp (53:32) Right? (53:32) That's unfortunate. (53:33) Yeah.
Scott Benner (53:34) Yeah. (53:34) And That's tough. (53:35) Yeah. (53:35) Yeah. (53:35) And so but I know if she didn't.
Scott Benner (53:37) I know if somebody else was here, and we could mess around with it a little bit. (53:40) I know there's an amount she should get, and I know we could figure out the pacing of it. (53:45) And it would be much less, maybe more frequently. (53:49) And I think it would change her life. (53:51) Yeah.
Scott Benner (53:51) Like, seriously.
David Knapp (53:52) Yeah. (53:53) Two things that I would just posit to you as something to to muse on over the next week. (53:58) The first thing is that with tirzepatide, if if that's the molecule that she wants to stick with, there are compounding pharmacies who do make it in oral form. (54:11) That said, they're not FDA approved. (54:13) They're not FDA inspected for you know, like, it's it's compounded medication.
David Knapp (54:19) So it it, by nature, is outside of the FDA system, but it's still a prescription you get from a doctor Mhmm. (54:24) And take under doctor supervision. (54:26) There are sublinguals. (54:27) There are and so the these compound pharmacies have found a way to protect these peptides and make them oral bioavailable. (54:33) But the question is, we don't know how much because they've never gone through clinical trials.
David Knapp (54:37) And frankly, the pharmaceutical companies pay billions of dollars for technology to make peptides orally bioavailable. (54:43) But if you can set that aside and know that that that is an option that you could explore and talk to her doctor about. (54:49) The second is when we talk about tirzepatide specifically on the injectable side, the interesting thing about tirzepatide is the half life on tirzepatide is, like, five days on average, where semaglutide is seven. (55:01) And so it's pretty normal for the those effects to kinda sort of fall off a cliff towards the end of that week when you're getting a couple days away from injection day. (55:11) And I firmly believe, like, to build on our earlier conversation about clinical trials, they chose seven days because seven days is easier for people to manage.
David Knapp (55:19) Yeah. (55:20) Not because it's ideal for the patient. (55:22) And, again, it's easier for the insurance companies. (55:24) It's easier for the pharmacies. (55:25) It's easier for the manufacturers to just four pens one month once a week.
David Knapp (55:29) Yeah. (55:29) But at the end of the day, it's probably not what's best for the patient every time.
Scott Benner (55:33) Do you know there's actual, like, human problem in that too, which is that when people feel better, one of the first things they do is stop doing the thing that helps them feel better.
David Knapp (55:41) A 100%. (55:42) Yeah. (55:42) Right?
Scott Benner (55:42) That's very common. (55:43) So Right. (55:44) You're in a terrible conundrum. (55:46) You'd start taking this injection. (55:47) Three months later, your whole life's different.
Scott Benner (55:49) And then, you know, you get the Saturday, and you're like, you don't even remember you don't feel well, and you don't think about the pen that's in the back of the refrigerator. (55:55) The other I mean, there's different issues there. (55:57) So do you think that for in my daughter's example, as I explained it, she'd be better off on Ozempic?
David Knapp (56:02) I don't know. (56:02) Because the mol tirzepatide, again, is is more GIP than it is GLP one. (56:09) It's it's it's a different hormone that it's focused on. (56:12) Although it's two, it's more so a GIP. (56:15) And so it's gonna be a different experience on semaglutide Ozempic than it is on Mounjaro.
David Knapp (56:20) And so I don't know the answer to that, but I do know that you you may she may experience and if she gets similar effects on the blood sugar control side from semaglutide, that, theoretically, it should last longer because the half life of the drug is longer.
Scott Benner (56:38) Yeah.
David Knapp (56:39) But it does seem to me, like, when you talk when you look at the studies, I can't remember what they actually are in type two diabetics. (56:47) So you can look at the SURPASS study for Mounjaro, and you can look at the can't remember what the one for Wegovy or for Ozempic was off the top of my head, but you can look at them and show it'll show you that Mounjaro is better at controlling a one c, and I think it's because of that GIP mechanism. (57:04) But you may get a a steadier peak and trough of the concentration of the drug with Ozempic just because of that seven day half life.
Scott Benner (57:12) It sounds like maybe if I wait, I can get Humalog with, GLP and GIP in it.
David Knapp (57:16) I I can't remember. (57:17) I can look it up here, but, insulin Novo Nordisk. (57:21) It's insulin icodec. (57:24) Does that sound right? (57:25) Insulin icodec.
David Knapp (57:27) There's there's one that they're that they're looking at for with Novo Nordisk. (57:32) And I I don't know. (57:33) It's it's the insulin icodec is a is a once weekly, right, just like like, Ozempic is.
Scott Benner (57:39) Oh, okay.
David Knapp (57:39) Right? (57:40) So it's it's supposed to give, you know, a smoother experience for somebody taking it and less sort of variability in the peaks and troughs of of that. (57:49) And so they're looking at combining it with with, GLP one. (57:53) Listen.
Scott Benner (57:54) Hopefully, it gets there for people who could be help I'll say this too. (57:57) I've seen people on on, type ones who use it, and it doesn't touch their insulin needs at all. (58:02) And that always makes me wonder, are these people who have type one diabetes but don't have other metabolic issues?
David Knapp (58:07) I wonder too if it it just really comes down to what level of beta cell function you have, if any. (58:14) Because in some really small clinical studies, they've shown clinically that they can give type one diabetics GLP one semaglutide, and they they come like, ninety percent of them come off all of their insulin at the right doses. (58:30) But this is a small trial, and you have to have some level of beta cell function in order to to have that happen because you have to be able to rely on your own insulin.
Scott Benner (58:40) Yeah. (58:40) It makes me think about this, researcher I I interviewed, like, fifteen years ago who was, like, positive. (58:45) She was like, I I sometimes feel like the beta cells aren't dead. (58:48) They're, like, so inflamed that they can't work is how she put it. (58:52) Mhmm.
Scott Benner (58:52) And I'm wondering, like I mean, that's a very, like, layman's, like, remembrance of her conversation. (58:57) But, like Right. (58:58) I do wonder, like, somewhere in there, there's a lot of things to be learned. (59:02) Like, hopefully, those companies are digging in labs on all of this stuff. (59:07) Right?
Scott Benner (59:07) Because
David Knapp (59:07) Oh, yeah.
Scott Benner (59:08) You know, I hear people all the time say, like, well, they'll put themselves out of business. (59:11) I'm like, the truth is if you took care of all the problems people had and that's what put you out of business, I think you'd have enough money to make it. (59:18) Mhmm. (59:18) There's that kind of cynical, like, they wanna have some of the money forever. (59:22) I think if you got all the money right now, they'd probably be happy to, you know, turn that money into a bank and stop being a pharma company and and and and on your way.
Scott Benner (59:30) I also don't want them to go out of business, obviously. (59:32) It's a it's a weird balance. (59:33) Right? (59:34) Like, to your point, like, you know, they're out there. (59:37) They're doing this work, and they're also trying to maximize their profits.
Scott Benner (59:40) It's hard to argue that I mean, I I understand what they're doing. (59:43) We don't want them not out there. (59:45) And, you know, you also want them making money and hiring good people, and it would also be nice if this stuff was affordable for people who were really, you know, in the trenches and needed it every day. (59:55) I mean Yeah. (59:56) Honestly, you know, $500 it's down to 500 a month now for people, and people are like, oh, it's cheaper.
Scott Benner (1:00:02) I'm like, my god. (1:00:02) That's still so expensive. (1:00:04) Yeah. (1:00:04) Yeah.
David Knapp (1:00:05) But the the good news is that with the addition of GLPs for obesity to Medicare, Medicare recipients are gonna pay $50 a month for it. (1:00:14) The government arbitrated their price down to 250. (1:00:18) Mhmm. (1:00:18) And so Medicare patients will get it for a $50 co pay. (1:00:21) Medicaid's gonna follow because they're gonna get the same pricing.
David Knapp (1:00:24) So most states will follow, and those folks won't even pay a co pay. (1:00:29) And then for the rest of the people, the deal with the most favored nations is that you'll be able to cash pay these things over the next twenty four months to get these down, both Wegovy, which is the obesity version of Ozepic, and and Zepbound, the obesity version of Mounjaro. (1:00:45) You'll be able to get those both for $250 within the next twenty four months, and the price just came down on the cash pay
Scott Benner (1:00:51) for it. (1:00:51) Then I'm thinking everybody should buy stock in companies that make clothes like bras and underwear and stuff that
David Knapp (1:00:56) Oh, yeah. (1:00:57) Yeah. (1:00:57) Because you
Scott Benner (1:00:58) have any idea how many times I've donated my clothes and had to rebuy stuff over the last two years? (1:01:02) Like, it's
David Knapp (1:01:03) Oh, yeah. (1:01:03) Yeah. (1:01:03) It's a there's a huge clothes swap market that goes on within the community of people who use these That's brilliant. (1:01:11) Drugs. (1:01:11) That's brilliant.
Scott Benner (1:01:12) Well so, Dave, I thank you. (1:01:14) I have taken up a lot of your time. (1:01:15) I I wondered, do you see it, I don't know, an avenue here where you and I could get back together and do this every once in a while? (1:01:20) Like, you
David Knapp (1:01:20) I would I mean, I I this is my world. (1:01:23) I love talking about this stuff. (1:01:25) I love talking to other people who are passionate about health. (1:01:28) And frankly, I just like talking to other laypeople that, you know, like you said, steeped in this stuff, immersed in it every day. (1:01:35) We've learned about this stuff because we're passionate, and we have skin in the game ourselves.
David Knapp (1:01:40) And I just think it's it helps a lot of people to hear from from other people like us. (1:01:45) So I would love to do more of this if you're willing to.
Scott Benner (1:01:47) We're gonna have to find an overlap with my audience's needs and your skill set and and your and your knowledge and and and find a way to we can do that. (1:01:56) We'll do that offline.
David Knapp (1:01:56) For sure. (1:01:57) Yeah. (1:01:57) There's a lot of people in the OnDePen community who are type one, and they're pining for more information just like you are on this stuff because everything is so focused on type two and obesity. (1:02:09) And they're saying, wait. (1:02:11) You know, my husband went on Mounjaro, he's a type one, and he's off his insulin, or he was able to greatly reduce his insulin.
David Knapp (1:02:18) What are they what are the trials saying? (1:02:20) And there's just been very little in terms of looking at GLP ones with type one, but I think that's because it's such a spectrum of disease in terms of how severe it is for people. (1:02:32) So it's hard to put together probably clinical trials for it.
Scott Benner (1:02:35) Well, yeah, also and it's scary to say out loud too because you don't wanna give people the idea that if they just took enough of this, their type one diabetes would stop needing insulin because I that's not gonna be the case for a great many people. (1:02:45) And, obviously, they would be impacted very poorly with their health for not taking their insulin. (1:02:50) You don't want that to be confused, and you also don't want people not to look into it.
David Knapp (1:02:54) Right?
Scott Benner (1:02:55) There's something there. (1:02:56) Like, I I think I told you before we started. (1:02:58) I've had, a gentleman on who's, you know, type one, and he's definitely type one. (1:03:03) People are like, well, maybe he wasn't, but he's definitely type one. (1:03:06) He has autoantibodies.
Scott Benner (1:03:07) He, you know, been using insulin for years. (1:03:09) They put him on Mounjaro or, you know, Zepbound for weight, and he literally came off his insulin. (1:03:15) Now he doesn't expect that's gonna be forever, but it is for now, and no one knows why. (1:03:20) It's not because GLP cures type one diabetes, which is how, like, simple black and white thinking ends up getting you know, people get very reactive when you say stuff like that. (1:03:30) But I've also had, you know, a 15 year old girl.
Scott Benner (1:03:34) Her mom came on to talk about how her insulin needs went down. (1:03:37) She was using one unit of basal a day. (1:03:39) She had to go off her pump. (1:03:40) She's an injected unit of basal a day. (1:03:42) She's back on a pump now, but it lasted two years.
Scott Benner (1:03:45) Like, two years where she wasn't taking a ton of insulin. (1:03:47) Right. (1:03:48) Somebody needs to be asking, like, what happened there? (1:03:50) Like, you you know what I mean? (1:03:52) Like, what was the functionality there?
Scott Benner (1:03:53) Like, what that's the stuff I want people looking into. (1:03:55) I don't think that if you just gave a type one enough enough GLP, they'd stop needing insulin. (1:04:01) Like, no one's saying that. (1:04:03) Like, I think you can hear there's a bigger conversation here about other impacts on your life. (1:04:08) And even if it just man, if it just makes something better for you, I I just I think it's really valuable to hear about more of it.
David Knapp (1:04:15) Right. (1:04:16) You
Scott Benner (1:04:16) know? (1:04:16) And then there's the functional side of it, like, actually implementing it. (1:04:19) You can start shooting this into people who don't really understand their insulin. (1:04:22) Like, you know, we've talked a lot today about, like, it would be nice if people could dose this themselves. (1:04:27) Mhmm.
Scott Benner (1:04:27) Insulin's a thing that type ones dose themselves all day long. (1:04:30) And trust me, Dave, between me and you, they're not great at it. (1:04:33) The doctors aren't great at giving you the right doses and you're and people aren't great at making the adjustments they need to make for a lot of good reasons. (1:04:41) And just flopping them on a GLP and and and reducing their needs right away, they might struggle to get their insulin, like, readjusted, which will cause them a lot of problems. (1:04:52) And some of those problems could be, you know, a dangerous hypoglycemia, hyperglycemia.
Scott Benner (1:04:57) And, obviously, you don't want that too. (1:04:58) And then you get into that more functional human problem of, like, how do you put this into practice? (1:05:04) And, I mean, I don't have any answers for that. (1:05:06) But for the people who can figure out how to do it on their own and you feel like you're up to the task, I'd look into this if I was you. (1:05:13) So A 100%.
Scott Benner (1:05:15) Alright.
David Knapp (1:05:15) Everything I I think you probably would echo this. (1:05:18) Everything that I share as a layperson here about this stuff, we just want people to have better conversations with their doctor. (1:05:25) And so that's always my hope whenever I share any of the information that I've learned is just you heard about a study. (1:05:31) You heard about a drug. (1:05:32) You heard about something that might help.
David Knapp (1:05:33) Go talk to your doctor about it. (1:05:35) And if your doctor doesn't know about it, ask them to know about it
Scott Benner (1:05:40) Yeah.
David Knapp (1:05:40) Or find somebody that does.
Scott Benner (1:05:42) Dave, I don't think there's any doubt that shows like yours and shows like mine, I think they push innovation forward because people can find out about things sooner. (1:05:51) Like, you know, forty years ago, like, you'd be like, do you, you know, do you have Pat? (1:05:55) She lives, like, three doors down. (1:05:57) She's taken the GLP. (1:05:59) That would take years for that to spread through the neighborhood, but it wouldn't help anybody.
Scott Benner (1:06:03) Right? (1:06:03) Like, you can yell it out loud now and have 10,000, 20,000, a million people hear it, and and you're not trying to make them do something. (1:06:10) You're trying to make them go home and quietly go, I wonder. (1:06:15) Mhmm. (1:06:15) What should I be asking for myself on this?
Scott Benner (1:06:17) You you know? (1:06:18) And then I think that's why this podcast works for people with type one too because I don't see a lot of difference between what we're talking about here and what ends up happening to people when they're diagnosed with type one or type two diabetes, honestly. (1:06:29) He gets sent home with, like, here, take metformin. (1:06:32) You'll be fine. (1:06:33) That's it?
Scott Benner (1:06:33) That's what you're gonna tell me? (1:06:35) So, anyway, I appreciate this very much. (1:06:37) Let me say goodbye to you, and and thank you very much for your time.
David Knapp (1:06:39) Thank you, Scott. (1:06:40) Yeah. (1:06:40) Appreciate it.
Scott Benner (1:06:47) This episode of the Juice Box podcast is sponsored by Omnipod five. (1:06:51) Omnipod five is a tube free automated insulin delivery system that's been shown to significantly improve a one c and time in range for people with type one diabetes when they've switched from daily injections. (1:07:02) Learn more and get started today at omnipod.com/juicebox. (1:07:07) At my link, you can get a free starter kit right now. (1:07:09) Terms and conditions apply.
Scott Benner (1:07:11) Eligibility may vary. (1:07:12) Full terms and conditions can be found at omnipod.com/juicebox. (1:07:17) Today's episode is also sponsored by US Med dot com slash juice box or call (888) 721-1514. (1:07:26) Get started today and get your supplies from US Med. (1:07:30) A huge thanks to Cozy Earth for sponsoring this episode.
Scott Benner (1:07:33) Don't forget Black Friday has come early at cozyearth.com. (1:07:36) Right now, you can stack my code JuiceBox on top of their site wide sale. (1:07:41) This is gonna give you up to 40% off in savings, and these deals are definitely not gonna last. (1:07:46) I'm talking about sheets, towels, clothing, everything they have. (1:07:49) Get that holiday shopping going right now today.
Scott Benner (1:07:52) Do it. (1:07:52) Do it. (1:07:52) Do it. (1:07:53) Cozyearth.com. (1:07:54) Use the off code juice box.
Scott Benner (1:07:56) Thank you so much for listening. (1:07:57) I'll be back very soon with another episode of the juice box podcast. (1:08:01) If you're not already subscribed or following the podcast in your favorite audio app, like Spotify or Apple podcasts, please do that now. (1:08:09) Seriously, just to hit follow or subscribe will really help the show. (1:08:13) If you go a little further in Apple Podcasts and set it up so that it downloads all new episodes, I'll be your best friend.
Scott Benner (1:08:19) And if you leave a five star review, oh, I'll probably send you a Christmas card. (1:08:24) Would you like a Christmas card? (1:08:27) Hey. (1:08:28) I'm dropping in to tell you about a small change being made to the Juice Cruise 2026 schedule. (1:08:33) This adjustment was made by Celebrity Cruise Lines, not by me.
Scott Benner (1:08:36) Anyway, we're still going out on the Celebrity Beyond cruise ship, which is awesome. (1:08:40) Check out the walkthrough video at juiceboxpodcast.com/juicecruise. (1:08:45) The ship is awesome. (1:08:47) Still a seven night cruise. (1:08:49) It still leaves out of Miami on June 21.
Scott Benner (1:08:52) Actually, most of this is the same. (1:08:53) We leave Miami June 21, head to Coco Cay in The Bahamas, but then we're going to San Juan, Puerto Rico instead of Saint Thomas. (1:09:01) After that, Bastirie, I think I'm saying that wrong, Saint Kitts And Nevis. (1:09:05) This place is gorgeous. (1:09:07) Google it.
Scott Benner (1:09:08) Mean, you're probably gonna have to go to my link to get the correct spelling because my pronunciation is so bad. (1:09:12) But once you get the Saint Kitts and you Google it, you're gonna look and see a photo that says to you, oh, I wanna go there. (1:09:19) Come meet other people living with type one diabetes from caregivers to children to adults. (1:09:25) Last year, we had a 100 people on our cruise, and it was fabulous. (1:09:30) You can see pictures to get at my link juiceboxpodcast.com/juicecruise.
Scott Benner (1:09:35) You can see those pictures from last year there. (1:09:37) The link also gives you an opportunity to register for the cruise or to contact Suzanne from Cruise Planners. (1:09:43) She takes care of all the logistics. (1:09:45) I'm just excited that I might see you there. (1:09:48) It's a beautiful event for families, for singles, a wonderful opportunity to meet people, swap stories, make friendships, and learn.
Scott Benner (1:09:57) If you're new to type one diabetes, begin with the bold beginnings series from the podcast. (1:10:01) Don't take my word for it. (1:10:03) Listen to what reviewers have said. (1:10:05) Bold beginnings is the best first step. (1:10:08) I learned more in those episodes than anywhere else.
Scott Benner (1:10:11) This is when everything finally clicked. (1:10:12) People say it takes the stress out of the early days and replaces it with clarity. (1:10:16) They tell me this should come with the diagnosis packet that I got at the hospital. (1:10:21) And after they listen, they recommend it to everyone who's struggling. (1:10:24) It's straightforward, practical, and easy to listen to.
Scott Benner (1:10:28) Bold Beginnings gives you the basics in a way that actually makes sense. (1:10:32) The Juice Box podcast is edited by Wrong Way Recording. (1:10:37) Wrongwayrecording.com. (1:10:40) If you'd like your podcast to sound as good as mine, check out Rob at wrongwayrecording.com.
Please support the sponsors
The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here. Recent donations were used to pay for podcast hosting fees. Thank you to all who have sent 5, 10 and 20 dollars!
